IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+7.37%)
Close on Nov 17, 2026Market cap $19.43MP/E –Yield –
IGC Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
IGC Pharma's revenue for the twelve months ending Jun 30, 2026 was $1.12M, down 15.4% year over year. For fiscal 2025 it was $1.27M, down 5.5% from the year before. Over ten years it grew -16.5% a year on average. The highest annual figure on record is $8.03M in fiscal 2013.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.27M | -5.5% |
| FY2024 | Mar 31, 2024 | $1.35M | +47.6% |
| FY2023 | Mar 31, 2023 | $911.00K | +129.5% |
| FY2022 | Mar 31, 2022 | $397.00K | -55.8% |
| FY2021 | Mar 31, 2021 | $898.00K | -77.9% |
| FY2020 | Mar 31, 2020 | $4.07M | -20.4% |
| FY2019 | Mar 31, 2019 | $5.12M | +133.3% |
| FY2018 | Mar 31, 2018 | $2.19M | +277.9% |
| FY2017 | Mar 31, 2017 | $580.37K | -90.9% |
| FY2016 | Mar 31, 2016 | $6.37M | -17.1% |
| FY2015 | Mar 31, 2015 | $7.68M | +237.9% |
| FY2014 | Mar 31, 2014 | $2.27M | -71.7% |
| FY2013 | Mar 31, 2013 | $8.03M | +91.2% |
| FY2012 | Mar 31, 2012 | $4.20M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $265.00K | -19.2% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $317.00K | -3.9% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $350.00K | +36.2% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $191.00K | -53.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $328.00K | +20.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $330.00K | +11.9% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $257.00K | +26.0% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $412.00K | +41.6% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $272.00K | -51.0% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $295.00K | +77.7% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $204.00K | -38.6% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $291.00K | +44.1% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $555.00K | +161.8% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $166.00K | +36.1% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $332.00K | +133.8% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $202.00K | +260.7% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $212.00K | +175.3% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $122.00K | +50.6% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $142.00K | +31.5% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $56.00K | -55.2% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $77.00K | -86.8% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $81.00K | +179.3% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $108.00K | -81.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $125.00K | -93.1% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $584.00K | -64.6% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $29.00K | -98.1% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $573.00K | -55.4% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $1.82M | +124.5% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $1.65M | +11.6% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $1.54M | +35.0% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $1.29M | +68.6% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $811.00K | +245.1% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $1.48M | +2692.6% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $1.14M | +1127.9% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $762.00K | +205.0% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $235.00K | +44.9% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $52.93K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $93.01K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $249.80K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $162.16K | – |
See a number that looks wrong?